J&J's Pulmonary Push

J&J doubles disclosed respiratory pipeline in deals with RespiVert, Orexo

In a pair of deals last week, Johnson & Johnson doubled the number of compounds in its disclosed pipeline for respiratory diseases from four to eight, and it sounds like the pharma is still shopping.

J&J's Centocor Ortho Biotech Inc. unit acquired RespiVert Ltd., a private U.K. company with two lead compounds in preclinical development for asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Separately, Orexo AB granted J&J's Ortho-McNeil-Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica N.V. subsidiaries exclusive, worldwide rights to develop and commercialize two compounds to treat asthma, COPD and other inflammatory conditions.

Centocor Ortho

Read the full 961 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE